Several other urinary biomarkers have been identified as indicators for the prediction and diagnosis of AKI, including liver fatty-acid-binding protein (L-FABP) [186], neutrophil gelatinase-associated lipocalin (NGAL) [187,188], kidney injury molecule-1 (KIM-1) [189], N-acetyl-β-D-glucosaminidase (NAG) [190], tissue inhibitor metalloproteinase-2 (TIMP-2), insulin growth factor binding protein-7 (IGFBP-7) [191,192], and urinary thioredoxin [193]. This evidence concerns the gene LCN2 and acute kidney injury.